coronavirus solutions

15 more COVID-19 research projects receive funds from Houston university

Rice University identified 15 more pandemic-related research projects to receive support from a new research fund. Getty Images

Researchers at a Houston institution have been rewarded for their work that focuses on COVID-19 and how it's affected various aspects of life.

Rice University has named its two more rounds of recipients of its COVID-19 Research Fund — an initiative created to support projects that are innovating solutions and services amid the COVID-19 crisis. In April, the COVID-19 Research Fund Oversight and Review Committee — led by engineering professor and special adviser to the provost, Marcia O'Malley — selected four projects led by Rice faculty members across industries from biomedicine to humanities that will receive the first round of funds.

The committee named another round of recipients in May and the third and final round this month. Here are the projects from the last two rounds of grants:

  • Rapid point-of-care device to detect severe cases of COVID-19 by Kevin McHugh and Peter Lillehoj of Rice and Cassian Yee of the University of Texas MD Anderson Cancer Center.
  • A mobile phone-based blood serum test for COVID-19 antibodies by Lillehoj, Wen Hsiang Chen of Baylor College of Medicine and James Le Duc of Galveston National Laboratory. The mobile test would be faster and more precise.
  • A handbook addressing pandemic response initiatives for health officials by Kirsten Ostherr and Lan Li of Rice; Thomas Cole of the McGovern Medical School at the University of Texas Health Science Center, Houston; Robert Peckham of Hong Kong University; and Sanjoy Bhattacharya of York University.
  • A look at COVID-19's effect on vehicle travel and electric power generation and air quality by Daniel Cohan and Daniel Kowal of Rice. Using both on-the-ground and satellite data, the researchers will look at various air pollutants.
  • A study on Harris County residents' compliance to stay-at-home orders by Flavio Cunha, Patricia DeLucia, Fred Oswald, Ekim Cem Muyan and E. Susan Amirian of Rice. The researchers will survey residents — particularly low-socioeconomic populations.
  • A look at how pollution and economics affect each other turing a pandemic-caused crisis by Sylvia Dee, Ted Loch-Temzelides, Caroline Masiello and Mark Torres of Rice. Thanks to stay-at-home initiatives, the study can look at which economic sectors contribute the most to carbon emissions.
  • A study on long-term effects of COVID-19 on human development by Fred Oswald of Rice, Rodica Damian and Tingshu Liu of the University of Houston and Patrick Hill of Washington University. The project looks at the pandemic's affect on social contexts including occupational, educational, community, family, lifestyle, health and financial.
  • A predictive model of Houston's COVID-19 condition by Daniel Kowal, assistant professor of statistics, and Thomas Sun, a graduate student, at Rice. The project will compare Houston to locations that are similar and further along the disease incidence curve.
  • A survey of how stay-at-home orders affected low-income families by Amelyn Ng, Wortham Fellow at Rice Architecture, and Gabriel Vergara of One Architecture and Urbanism. he survey will focus on Houston's Greater Fifth Ward.
  • Research on antibodies for disease prevention by Laura Segatori, associate professor of bioengineering and of chemical and bimolecular engineering and biosciences, and Omid Veiseh, assistant professor of bioengineering, at Rice. The two scientists plan to engineer cell lines for the rapid development of clinically translatable neutralizing antibodies for infection control.
  • An analysis of working conditions amid the pandemic by Danielle King, assistant professor of psychological sciences at Rice. King will look into both employees who can no longer go to the workplace, like teachers, and those required to, like nurses, to see what resources are most effective.
  • An oxygen sensing device by Michael Wong, department chair and a professor of chemical and biomolecular engineering, and Rafael Verduzco, associate professor of chemical and biomolecular engineering, of Rice and John Graf of NASA. The team will continue working on a NASA-designed prototype ventilator for rapid deployment based on an off-the-shelf automotive oxygen sensor.
  • A study on social distancing for musicians by Ashok Veeraraghavan, Robert Yekovich and Ashutosh Sabharwal of Rice and John Mangum of the Houston Symphony. The project will look into airflow of wind instruments using high-speed imaging.
  • Looking into public health initiatives and their use in COVID-19 by Hulya Eraslan, Rossella Calvi, Dibya Deepta Mishra and Ritika Sethi of Rice. The team will look at election data with a goal is to understand the impact of political alignment across levels of government on the effectiveness of its response.
  • Research on optimizing nursing staff schedules by Andrew Schaefer, Illya Hicks and Joseph Huchette of Rice and Nicole Fontenot of Houston Methodist Hospital. Researchers will employ data and technology to improve forecasting demand for nursing staff.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News